Evidence map›Paper›PMID 31606963›Full record

ArticleCell journal2020

Indirect Tumor Inhibitory Effects of MicroRNA-124 through Targeting EZH2 in The Multiple Myeloma Cell Line.

Javid Sabour Takanlu, Arad Aghaie Fard, Saeed Mohammdi, Seyed Mohammad Ali Hosseini Rad, Saeid Abroun, Mohsen Nikbakht

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cell journal, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.5field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 8 citations in OpenAlex.

  1. Review
  2. Multiple Myeloma: Genetic and Epigenetic Biomarkers with Clinical Potential.International journal of molecular sciences · 2024
    Article
  3. Review
  4. Review
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 2 countries.

Javid Sabour Takanlu *Department of Hematology, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran.
Arad Aghaie Fard *Department of Hematology, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran.
Saeed MohammdiHematology, Oncology and Stem Cell Transplantation Research Center, Tehran University of Medical Sciences, Tehran, Iran.
Seyed Mohammad Ali Hosseini RadDepartment of Microbiology and Immunology, University of Otago, Dunedin, New Zealand.
Saeid AbrounDepartment of Hematology, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran. Electronic Address:abroun@modres.ac.ir.
Mohsen NikbakhtHematology, Oncology and Stem Cell Transplantation Research Center, Tehran University of Medical Sciences, Tehran, Iran.
Tehran University of Medical Sciences · IRTarbiat Modares University · IRUniversity of Otago · NZ

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveMultiple myeloma (MM) is an incurable plasma cell malignancy. Several genetic and epigenetic changes affect numerous critical genes expression status in this disorder. MATERIALS AND

methodsIn this experimental study, growth inhibitory effects of miR-124 were measured by MTT assay in L-363 cell line. Likewise, cell cycle assay was measured by flowcytometery. The expression levels of

resultsqRT-PCR results showed induction of

conclusionIt seems that assembling of H3K27me3 mark mediated by EZH2 is one of the key mechanisms of suppressing

Indexed as

Cyclin-Dependent Kinase Inhibitor 2AEnhancer of Zeste Homolog 2MicroRNAMultiple Myeloma

Identifiers

PMID31606963
PMCPMC6791060
OpenAlexW2992370849

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.